21 September 2021 - - US-based precision immunology company ImmuneID, Inc has appointed James S. Scibetta as chief executive officer and a member of the board of directors, the company said.

Scibetta succeeds David Donabedian, Ph.D., Venture Partner of Longwood Fund, who had been serving as CEO and will serve in an advisory capacity to the company.

Scibetta joins ImmuneID after serving as CEO and a member of the board of directors of Maverick Therapeutics Inc., a biotechnology company pioneering conditionally active bispecific T-cell targeted immunotherapies that was acquired by Takeda in April 2021.

In this role, he led Maverick in the development of the COBRA Platform, which co-opts proteolytic activity in the tumor microenvironment to generate localized t-cell activation and cell killing.

Prior to Maverick, he held various executive leadership roles at Pacira Pharmaceuticals (NASDAQ: PCRX), including president, and previously CFO, overseeing global R and D, CMC, and capacity expansion activities for the development of their drug EXPAREL.

He led the company's 2011 IPO and subsequent debt and equity financings.

Previously, Scibetta served as CFO of Bioenvision Inc. (NASD: BVIN, acquired by Genzyme) and Merrimack Pharmaceuticals.

Scibetta began his career in investment banking, spending over a decade sourcing and executing transactions for a range of public and private healthcare and life sciences companies.

He received a B.S. in physics from Wake Forest University and an MBA from the University of Michigan.

ImmuneID's technology platform and the underlying technology is designed to provide insights into human immune response throughout the course of disease progression for the identification and validation of therapeutic targets.

The technology was originally developed in the lab of Stephen Elledge, Ph.D., ImmuneID co-founder and chair of ImmuneID SAB, Lasker Award winner and The Gregor Mendel Professor of Genetics and Medicine, Harvard Medical School.

ImmuneID is a precision immunology company creating novel and transformational therapies by combining powerful next-generation sequencing with robust protein display technologies to comprehensively characterize patient antibody interactions in immune diseases.

Our proprietary, unbiased platform rapidly and affordably identifies millions of antibody-target interactions to build the map of human immunity.

Through a combination of passionate bench science, insightful computational biology, and big data generation, ImmuneID will improve and personalize patient diagnoses to deliver precise treatments for immune-mediated diseases.

Founded in late 2020 by Longwood Fund, ImmuneID is headquartered in Cambridge, MA.